RALEIGH, N.C., and OXFORD, Mich., March 14 /PRNewswire/ -- Qualyst, Inc., a leading developer of proprietary ADMET research technologies, and Oxford Biomedical Research, Inc., widely recognized as a manufacturer of high quality biological reagents, assay kits and services, announced today the completion of an agreement under which Oxford has exclusively licensed intellectual property from Qualyst for the production of novel cytochrome P450 (CYP450) inhibition assays, to be sold as ACCURATE(TM). Terms of the agreement were not disclosed.
“Oxford Biomedical is an excellent partner to manufacture and distribute our patented technology, ACCURATE(TM), and look forward to our continued relationship,” said Marc Sedam, Qualyst’s Vice President of Corporate Development.
Oxford Biomedical’s CEO Denis Callewaert commented that “The combination of Qualyst’s improved technology for analysis of CYP activity, coupled with Oxford’s manufacturing experience will provide pharmaceutical toxicologists with a better way to evaluate drug metabolism and drug-drug interactions. The ACCURATE(TM) product line provides several key advantages that will make it very successful.”
The first product in the ACCURATE(TM) product line is an assay to detect the inhibition of CYP3A4, the enzyme most responsible for metabolizing xenobiotics. Estimates have placed the market for 3A4 inhibition screens at 80% of the total CYP450 screening market. The unique advantage of ACCURATE(TM) over existing technology is the ability to measure inhibition of CYP3A4 in the presence of more than one compound. ACCURATE(TM) for 3A4 inhibition is also more precise and reproducible than the current marketed technologies.
About Qualyst, Inc.
Qualyst commercializes novel and proprietary ADMET products for drug discovery and development. Qualyst’s products allow pharmaceutical and biotechnology researchers to make faster, better decisions regarding drug candidate compounds, saving valuable time and research dollars in the process. Qualyst, Inc. was founded on discoveries from breakthrough research at the University of North Carolina at Chapel Hill. For additional information, please refer to the company’s web site at www.Qualyst.com or call 919-313-6500.
About Oxford Biomedical Research, Inc.
Established in 1984, Oxford Biomedical Research is widely recognized as a manufacturer of high quality biological reagents, assay kits and services that produce “Consistently Reliable Results”. Our mission is to improve that mark and become your primary source for laboratory needs, primarily in the fields of Drug Metabolism, Oxidative Stress, and Eicosanoid Metabolism. For additional information, please refer to the company’s web site at www.Oxfordbiomed.com or call 800-692-4633.
Qualyst, Inc.; Oxford Biomedical Research, Inc.
CONTACT: Marc Sedam of Qualyst, Inc., +1-919-313-6511, orinfo@qualyst.com; or Denis Callewaert of Oxford Biomedical Research, Inc.,+1-800-692-4633, or info@oxfordbiomed.com
